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ABSTRACT
Background. Extended resections (i.e., major hepatec-
tomy and/or pancreatoduodenectomy) are rarely performed
for gallbladder cancer (GBC) because outcomes remain
inconclusive. Data regarding extended resections from
Western centers are sparse. This Dutch, multicenter cohort
study analyzed the outcomes of patients who underwent
extended resections for locally advanced GBC.
Methods. Patients with GBC who underwent extended
resection with curative intent between January 2000 and
September 2018 were identified from the Netherlands
Cancer Registry. Extended resection was defined as a
major hepatectomy (resection of C 3 liver segments), a
pancreatoduodenectomy, or both. Treatment and survival
data were obtained. Postoperative morbidity, mortality,
survival, and characteristics of short- and long-term sur-
vivors were assessed.
Results. The study included 33 patients. For 16 of the
patients, R0 resection margins were achieved. Major post-
operative complications (Clavien Dindo C 3A) occurred for
19 patients, and 4 patients experienced postoperative mor-
tality within 90 days. Recurrence occurred for 24 patients.
The median overall survival (OS) was 12.8 months (95%
confidence interval, 6.5–19.0 months). A 2-year survival
period was achieved for 10 patients (30%) and a 5-year
survival period for 5 patients (15%). Common bile duct,
liver, perineural and perivascular invasion and jaundice were
associated with reduced survival. All three recurrence-free
patients had R0 resection margins and no liver invasion.
Conclusion. The median OS after extended resections for
advanced GBC was 12.8 months in this cohort. Although
postoperative morbidity and mortality were significant,
long-term survival (C 2 years) was achieved in a subset of
patients. Therefore, GBC requiring major surgery does not
preclude long-term survival, and a subgroup of patients
benefit from surgery.
Gallbladder cancer (GBC) is a rare tumor. Worldwide
incidence rates are fewer than 2 per 100,000, with signif-
icant geographic variation.1,2 Nevertheless, it is the most
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common biliary tumor.3,4 Gallbladder cancer is character-
ized by locally aggressive behavior and early spread to
regional lymph nodes.1 Timely diagnosis of GBC is diffi-
cult due to the late, nonspecific symptoms and a tendency
for early metastatic spread.5 As a result, GBC is diagnosed
at an advanced stage in the majority of cases.6–8
Complete surgical resection is the only curative treat-
ment.9 The majority of long-term survivors are patients
with GBC diagnosed incidentally after cholecystectomy for
presumed benign gallbladder disease. Only 10% to 20% of
tumors diagnosed preoperatively, are amenable to resection
at presentation, and the prognosis after resection remains
unfavorable.10–14 Patients with T4 disease, even after rad-
ical resection, have a median overall survival (OS) period
of only 11 months.14
To achieve resection with tumor-free margins, extended
resections such as major hepatectomy, pancreatoduo-
denectomy (PD), and even hepatopancreatoduodenectomy
have been performed for advanced tumors.15–17 However,
extended resections are associated with significant post-
operative morbidity and mortality ([ 50%), whereas the
benefit in terms of survival remains unclear.15 Moreover,
almost all published studies are single-center series from
non-Western countries. Only two Western studies were
published more than one decade ago.15,18 Nationwide data
are essential for light to be shed on actual clinical outcomes
for GBC patients.
This study aimed to analyze the results of extended
resections for patients with advanced GBC in a Dutch
multicenter nationwide study, to determine postoperative
morbidity, mortality, and survival, and to identify factors
associated with short- and long-term survival.
METHODS
The study was approved by the Medical Ethics Com-
mittee of the Arnhem-Nijmegen region (METc no.
2017-3912) and conducted according to Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidelines for observational cohort studies.19
Patients were identified from the Netherlands Cancer
Registry (NCR). The NCR contains data on all newly
diagnosed malignancies including year of diagnosis,
patient age and gender, tumor characteristics (tumor-node-
metastasis [TNM] stage), patient identification number,
and treatment hospital. The data from the NCR are based
on data from the automated pathologic archive (PALGA),
the nationwide network, and the registry of histo- and
cytopathology in The Netherlands, supplemented by data
from the National Archive of Hospital Discharge
Diagnosis.20 Patients treated for GBC in any tertiary
referral center in The Netherlands were included in a
national, retrospective database.
Patient Selection and Variable Definitions
Patients with histopathologically proven GBC who
underwent extended resection were included in the current
study. Extended resection was defined as a major hepate-
ctomy (resection of C 3 liver segments), a PD, or both,
with or without en bloc resection of adjacent organs
(duodenum, colon, or stomach) with curative intent. The
study excluded patients who underwent a simple chole-
cystectomy, a resection or re-resection of the gallbladder
bed, a minor hepatectomy (\ 3 segments), and/or lymph
node dissection along the hepatoduodenal ligament without
associated major liver resection. Patients with incidentally
diagnosed GBC (i.e., during or after cholecystectomy for
presumed benign disease) also were excluded.
Data on patient characteristics, preoperative bilirubin
and carbohydrate antigen 19-9 (CA19-9), operative char-
acteristics, tumor characteristics, postoperative morbidity
and mortality, recurrence, and OS were obtained from the
medical records. Tumor staging was reported according to
the American Joint Committee on Cancer (AJCC) staging
system.21 Resection margins were classified as R0 (margin
distance to tumor C 1 mm) and R1 (micro- or macro-
scopically positive margin). Intraoperative hemorrhage was
defined as intraoperative blood loss of at least 1000 ml or
blood loss requiring a blood transfusion intraoperatively.
Data on postoperative complications were determined
according to the Clavien–Dindo classification system and
included complications up to 90 days after surgery.22
Major complications were defined as Clavien–Dindo grade
3A or higher. Postoperative mortality was defined as death
due to any cause within 90 days postoperatively.
Determination of OS included deaths from any cause.
Short-term survival was defined as survival up to 6 months,
including postoperative mortality. Long-term survival was
defined as survival 2 years or longer. Disease-free survival
was defined as the number of months from extended
resection to the date of recurrence or the date of the last
follow-up assessment. Adjuvant therapy was administered
only in a clinical trial setting because it was not considered
standard of care during the study period.
Statistical Analysis
Continuous variables are presented as median (in-
terquartile range), and categorical data are presented as
number (%). Survival was reported using Kaplan–Meier
methods, and differences in survival were analyzed using
the log-rank test. All p values of 0.05 or lower were
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considered statistically significant. All statistical analyses
were performed using SPSS Statistics for Windows, ver-
sion 23.0 (IBM Corporation, Armonk, NY, USA).
RESULTS
Patient Characteristics
Between January 2000 and September 2018, 289
patients underwent a surgical resection for pre- or post-
operatively diagnosed GBC with curative intent in the
participating centers. During this period, 33 patients with
pre-or intraoperatively diagnosed GBC (11%) underwent
an extended resection and were included in the study.
The cohort consisted of 13 men (39%) and 20 women
(61%). The median age at the time of diagnosis was
64 years (interquartile range [IQR], 57.0–68.5 years)
(Table 1). The presenting symptoms were jaundice
(n = 21), abdominal pain (n = 16), nausea (n = 8), weight
loss (n = 7), discolored defecation (n = 3), fever (n = 1),
back pain (n = 1), and liver enzyme disorders (n = 1). At
presentation, CA19-9 was tested in 12 patients and showed
a median value of 542 kU/l (IQR, 87–3500 kU/l). At pre-
sentation, bilirubin levels were available for 19 patients,
with a median value of 94 lmol/l (IQR, 12–159 lmol/l).
None of the patients were Asian or had a diagnosis of
primary sclerosing cholangitis (PSC).
Preoperative Workup and Treatment
The preoperative workup consisted of ultrasonography
(US) (n = 25), endoscopic US (n = 5), computed tomog-
raphy (CT) (n = 33), magnetic resonance imaging (MRI)
(n = 20), and positron emission tomography (PET)-CT
(n = 5). Preoperative imaging for 30 patients (91%)
showed adjacent organ invasion into the extrahepatic bile
ducts (n = 22, 67%), liver (n = 16, 49%), pancreas (n = 7,
21%), or duodenum (n = 1, 3%). Preoperative biliary
drainage was performed for 20 patients, and all 20 patients
(61%) underwent endoscopic retrograde cholangiopancre-
atography. For two patients (6%), an additional
percutaneous transhepatic cholangiography was required.
For eight patients (24%), a diagnostic laparoscopy was
performed. A portal vein embolization was performed for
five patients (15%). None of the patients received neoad-
juvant chemotherapy (NACT).
The indications for extended resection were suspicion
for GBC, cholangiocarcinoma (CCA), or pancreatic cancer
with invasion of adjacent organs. The main indications for
major hepatectomies were a suspicion of hilar CCA (n = 4)
or GBC with liver involvement, discovered on preoperative
imaging (n = 11) or intraoperatively (n = 4). One of these
patients had a clear indication for a major hepatectomy
instead of a minor hepatectomy, which could not be
obsoleted retrospectively. The main indications for a PD
were suspicion for distal CCA (n = 2), suspicion for pan-
creatic cancer (n = 2), GBC with pancreatic involvement
or suspicious lymph nodes around the pancreas preopera-
tively (n = 5), and GBC with involvement of the
duodenum intraoperatively (n = 3). The indication for
hepatopancreatoduodenectomy was GBC with involvement
of the liver and extension into the distal bile duct and portal
vein shown on preoperative imaging (n = 1) as well as
GBC with involvement of the liver and intraoperative
suspected lymph node invasion around the pancreas
requiring resection of the pancreatic head (n = 1).
TABLE 1 Patient and operative characteristics of gallbladder cancer
patients who underwent extended resection
Total (n = 33) n %















Left hemihepatectomy 1 (3)
Extended right hemihepatectomy 7 (21)
Right hemihepatectomy 11 (33)
Right hemihepatectomy ? PD 2 (6)
PD ? wedge 11 (33)







Yes, C CD3 19 (58)
IQR interquartile range, ASA American society of anesthesiologists,
PVE portal vein embolization, PD pancreatoduodenectomy, CD
Clavien–Dindo classification system
aEight missing values
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Operative Characteristics
The operative characteristics of the entire cohort are
presented in Table 1. The surgical procedures consisted of
right hepatectomy (n = 11), extended right hepatectomy
(n = 7), PD with wedge resection (n = 11), PD with con-
current segment 4 and 5 resection (n = 1) and left
hepatectomy (n = 1), and PD combined with right hepa-
tectomy (n = 2). Additionally, the colon was partially
resected due to intraoperative involvement in two cases,
and the ovaries were resected in one case. All the patients
underwent a lymph node dissection and resection of the
common bile duct (CBD). The portal vein was recon-
structed in 10 patients (30%).
Intraoperative complications occurred for five patients
(15%), consisting of hemorrhage in five patients and an
additional systemic inflammatory response syndrome
(SIRS) in one patient. All the intraoperative complications
occurred for patients who underwent a major hepatectomy
(Table 2).
Tumor Characteristics
Histopathologic analysis showed tumor-free margins in
16 patients (49%; Table 3). Histology showed adenocar-
cinoma (n = 29), squamous-cell carcinoma (n = 1), and
adenosquamous carcinoma (n = 1). The histopathologic
subtype was not described for two patients. Tumor differ-
entiation grade, reported for 22 patients, was good in 6
patients (27%), moderate in 9 patients (41%), and poor in 7
patients (32%). Perineural invasion was found in 24
patients (73%) and perivascular invasion in 16 patients
(49%).
Postoperative Morbidity and Mortality
Major postoperative complications within 90 days
occurred for 19 patients (58%), as described in Table 2.
Four postoperative deaths (12%) occurred, two due to
sepsis (because of liver failure or anastomotic leakage), one
due to liver failure after portal vein thrombosis, and one
due to aspiration and hypoxia.
Adjuvant Treatment, Follow-Up Evaluation,
and Survival
Two patients received adjuvant chemotherapy (gemc-
itabine and cisplatin for 1 patient and capecitabin for 1
patient), and five patients received chemotherapy with
palliative intent at the time of recurrence. Recurrence
occurred for 24 patients (73%) after a median disease-free
interval of 11 months (95% confidence interval [CI],
6.4–15.7 months). Imaging during follow-up assessment
showed recurrence locally (n = 13), on the peritoneum
(n = 10), in the liver (n = 9), in the lungs (n = 1) and at
other locations (n = 7). All mortality was disease-related
(i.e., due to postoperative complications, progression, or
recurrence).
The median OS was 12.8 months (95% CI,
6.5–19.0 months; Fig. 1a) after a median follow-up period
of 13 months. The median OS, excluding postoperative
mortality, was 15.9 months (95% CI, 9.1–22.7 months),
and the median disease-free survival was 10.1 months
(95% CI, 4.5–15.8 months).
No significant survival difference was found between
R0 and R1 resections. The median OS was 11.1 months for
the R0 patients versus 12.8 for the patients with a R1
resection (p = 0.203; Fig. 1B). Three patients were still
TABLE 2 Serious (C CD3a) postoperative complications within 90 days after extended resections in gallbladder cancer patients
Major hepatectomy (n = 19) n (%) PD (n = 12) n (%) Major hepatectomy ? PD (n = 2) n (%)
Postoperative complications C CD3 11 (58) 7 (58) 1 (50)
Intraabdominal abscess 1 3 0
Ascites 4 0 0
Abdominal hemorrhage 0 3 1
Anastomotic leakage 1 3 0
Pancreatic fistula 1 0 0
Respiratory 3 1 1
Cardiac 1 0 0
Liver failure 1 1 0
Sepsis/SIRS/systemic shock 4 3 0
Other 2 2 1
Postoperative mortality 3 (16) 1 (8) 0 (0)
PD pancreatoduodenectomy, CD Clavien–Dindo classification system, SIRS systemic inflammatory response syndrome
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alive without signs of disease at the time of this study
(median follow-up period, 97 months).
The characteristics of the short-term survivors
(B 6 months; n = 9) and the long-term survivors
(C 2 years; n = 10) are reported in Tables 4 and 5,
respectively. When the patients who died of postoperative
complications were excluded, eight of nine short-term
survivors showed jaundice at the time of presentation, and
all the patients showed perineural and perivascular inva-
sion, invasion of the liver parenchyma, and CBD in the
histopathologic analysis. All the long-term survivors
without recurrence (n = 3) showed tumor-free resection
margins without signs of perivascular invasion or liver
invasion in the histopathologic analysis. One long-term
survivor without recurrence received adjuvant
chemotherapy.
DISCUSSION
This national, retrospective cohort analysis is the first
Western study in the past decade to investigate the out-
comes of extended resections for GBC. This series showed
that major hepatectomies and PDs rarely are performed for
advanced GBC in The Netherlands. Despite a reported
median disease-free survival of 10.1 months and a median
OS of 12.8 months, 21% of the patients survived beyond
3 years. Major postoperative complications occurred for
58% of the patients and postoperative mortality for 12% of
the patients. In 49% of the patients, R0 resection margins
were achieved.
TABLE 3 Pathologic characteristics of gallbladder cancer patients
after extended resections































Squamous-cell carcinoma 1 (3)







































16 9 6 5 4 4
No. at risk
OS 33 18 10 7 5 5





FIG. 1 Overall survival (OS) in years
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In a study from the Memorial Sloan Kettering Cancer
Center,15 comparable mortality rates were described, with a
postoperative mortality rate of 14% (5 of 36 patients) for
major hepatectomies. Recurrence occurred for 24 patients
(73%). In that study, R0 resection margins were achieved
for 91% of the patients, and the 5-year survival rate was
27%. Nevertheless, in that study, some patients without
evidence of inflow involvement underwent empiric major
hepatectomy, whereas in our study all the patients except
one were suspected of tumor extension to other organs,
necessitating extended resection for tumor-free margins.
The value of extended surgery for advanced GBC
remains questionable. Results from previous studies
investigating patients undergoing hepatopancreaticoduo-
denectomy show virtually no survival beyond 2 years and a
R0 resection rate of only 20%.23,24 In our cohort, the 2-year
survival rate was 30% and the 5-year survival rate was
12%. The patients with an R0 resection (achieved for 49%)
had a 5-year survival rate of 19%. Multivariable analysis in
a previous study by Fong et al.25 showed that the extent of
liver resection did not influence long-term survival.
Another study argued that wedge resection is to be reserved
for patients with minimal liver invasion and that extensive
liver resections should be performed for patients who have
advanced tumors with extensive liver invasion or hepatic-
hilar-type tumors.26 Unfortunately, due to low numbers of
patients, we could not study the association between extent
of liver invasion, resection, and survival. However, it is
known from a population-based study that the 1-year sur-
vival rate for patients with unresected, advanced GBC is
less than 10%, versus a 1-year survival of 55% and a
median OS of 12.8 months in our cohort including patients
who died of surgery-related complications.27 The median
OS of all patients who had unresected GBC treated with
palliative chemotherapy was 6.4 months in our nationwide
cohort (unpublished results). Moreover, in the ABC-02 trial
(gemcitabine ? cisplatin vs gemcitabine alone for unre-
sected biliary tract cancer), no survivors beyond 3 years
were reported, whereas our cohort had a 3-year survival
rate of 20%.28
Although no significant survival difference between R0
and R1 patients was observed, all three long-term survivors
without recurrence clearly had R0 resection margins. The
lack of a statistically significant difference therefore was
most likely caused by our small sample size. Other
explanations include possible per-centra and over-time
differences in R0 or R1 resection margin criteria as well as
differences in experience and quality of pathologists.
TABLE 4 Characteristics of short-term survivors (B 6 months)
Age (years),a
gender, ASA














66, M, 3 Yes RH T4N0M0
R0
Yes Yes Yes No 6 Postop
comp
77, M, NA Yes RH T3N1M0
R1
Yes Yes Yes Yes 10 Postop
comp
73, M, 2 Yes RH T3N0Mx
R1
Yes No Yes Yes 10 Postop
comp
64, F, NA Yes PD T4N1M1
R1
Yes Yes Yes Yes 17 Postop
comp
64, F, 2 Yes PD T3N2M1
R0
Yes Yes Yes Yes 63 Progression
70, F, 3 No RH T4N1M0
R1
Yes Yes Yes Yes 130 Progression
58, F, 3 Yes PD T4N2M1
R1
Yes Yes Yes Yes 141 Progression
64, M, 2 Yes Ext RH T3N1M0
R1
Yes Yes Yes Yes 155 Progression
67, M, NA Yes Ext RH T3N0M0
R0
Yes Yes Yes Yes 157 Recurrence
ASA American society of anesthesiologists, pTNM pathologic tumor-node metastasis, CBD common bile duct, M male, RH right hemihepate-
ctomy, Postop comp postoperative complications, F female, PD pancreatoduodenectomy, Ext RH extended right hemihepatectomy, NA not
available
aAt presentation
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Identification of prognostic factors is vital for adequate
patient selection. Our results show that except for a short-
term survivor, all the patients were jaundiced at presenta-
tion, a factor known to have a negative influence on
survival.29 Additionally, all the short-term survivors had a
pT3 or pT4 stage tumor, and the majority had positive
lymph nodes. In contrast, few long-term survivors had a
high T stage and positive lymph nodes. Except for the
patients who died of postoperative complications, all the
short-term survivors had both perivascular invasion and
invasion of the liver parenchyma. These factors also were
associated with poor survival in other studies.24,30,31
In-depth preoperative assessment using imaging tech-
niques such as contrast-enhanced MRI may identify
patients with smaller, localized tumors amenable to
resection.32 The use of PET scans and PET-CT scans might
be especially helpful in detecting unsuspected
metastasis.33–35
Although our cohort likely comprised a highly selected
subgroup of patients fit to undergo extensive surgery with
no suspicion for metastasis, our results demonstrate that for
these patients, long-term survival after extended surgery is
possible. However, the high morbidity and mortality rates
associated with extensive liver surgery need to be weighed
against the apparent survival benefit. Postoperative quality
of life (QoL) must be taken into account when extended
resection is considered. Unfortunately, due to the retro-
spective nature of this study, we were not able to assess
QoL by using questionnaires.
Identification of the correct tumor type and location
preoperatively may be difficult in GBC. In 12 of 33 cases
of our series, CCA or pancreas carcinoma was suspected
instead of GBC preoperatively. Infiltration by tumor or
inflammation in surrounding tissues (i.e., pancreas, hilum
or extrahepatic bile ducts) makes identification of primary
tumor location on preoperative imaging challenging.
Moreover, differentiating malignant invasion in adjacent
organs from inflammation is difficult. In a study from
Memorial Sloan Kettering Cancer Center, a subgroup of
patients required resection of adjacent organs due to tumor
adhesion. Definitive histopathology showed tumor invasion
in only half of these patients.15
Results from the recently published BILCAP trial sug-
gest that adjuvant capecitabine can improve OS for patients
with resected biliary tract cancer.36 Currently, adjuvant or
neoadjuvant chemotherapy is not considered standard of
care in The Netherlands, as reflected by the small number
of patients in our cohort who received chemotherapy.37
TABLE 5 Characteristics of long-term survivors (C 24 months)
Age (years),a
gender, ASA













65, M, 2 Yes PD T3N0M0
R0
No No Yes No 24 Deceased,
recurrence
63, M, 2 Yes RH T2N0M0
R1
Yes Yes No No 24 Alive, with
recurrence
67, F, 2 No RH T4N1M0
R0
Yes No No No 27 Deceased,
recurrence
79, F, 2 No PD T2N2M0
R1
No Yes No No 29 Deceased,
recurrence
63, M, 3 Yes PD T4N1M0
R1
Yes No No No 39 Deceased,
recurrence
46, M, 2 Yes RH ? PD T3N1M0
R0
Yes Yes Yes Yes 49 Deceased,
recurrence
69, F, 2 Yes RH ? PD T4N2M1
R1
Yes No No No 71 Deceased,
recurrence
65, M, 3 No RH T3N0M0
R0
Yes No No Yes 86 Alive, no
recurrence
53, F, 1 No RH T2N2M0
R0
No No No No 91 Alive, no
recurrence
68, F, 2 No PD T3N0M0
R0
No No No No 119 Alive, no
recurrence
ASA American Society of Anesthesiologists, pTNM pathologic tumor-node metastasis, CBD common bile duct, M male, PD pancreatoduo-
denectomy, RH right hemihepatectomy, F female
aAt presentation
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However, one of three long-term survivors without recur-
rence received adjuvant capecitabine, providing additional
support for the use of adjuvant chemotherapy.
Moreover, a recent article reported significantly lower
recurrence rates and better OS for patients receiving
adjuvant chemoradiation therapy versus surgery alone for
resected GBC. Notably, this benefit was observed only for
patients with positive lymph node status, and patients with
N0 disease did not appear to benefit from adjuvant ther-
apy.38 Therefore, administration of adjuvant
chemoradiation might be helpful for pN1/2 patients fit to
undergo adjuvant therapy.
A recent systematic review stated that although favor-
able tumor response and increased resectability rates have
been reported after NACT, the evidence currently is
insufficient to support its routine use.39 However, the
authors also concluded that future randomized trials should
be conducted to investigate the role of NACT in advanced
GBC. Because radical resection seems to be the only way
long-term survival can be achieved, NACT before resec-
tion for locally advanced gallbladder cancer patients (e.g.,
the patients in our cohort) may further improve outcomes.
Our study had several limitations. First, the small
number of patients made it impossible to draw statistical
conclusions about prognostic factors for prolonged survival
after extended resections for GBC Second, due to the ret-
rospective nature of the study, a large amount of data were
missing. Unfortunately, prospective research is logistically
challenging due to the low incidence of this type of tumor.
Future international collaborative studies should include a
larger cohort of patients, preferably based on prospective
data collection.
In conclusion, median OS after major resection for
advanced GBC in our cohort was 12.8 months, and 10
patients survived longer than 2 years. Jaundice at the time
of presentation, perineural and perivascular invasion, pos-
itive lymph nodes, and invasion of the liver parenchyma
and CBD demonstrated via histopathologic examination
were present in patients with poor survival. Because major
postoperative complications were frequent and postopera-
tive mortality occurred in 12% of the patients, the
prognosis for these patients was extremely poor if no sur-
gery was performed. Therefore, extended resections for
patients with locally advanced GBC should be considered
if the morbidity and mortality rates are acceptable for the
patient compared with the presumed benefit in terms of
survival and QoL.
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